Municipal Elections - Reporting of Information to the State Board
HB1448 creates a new subtitle in the Health-General Article governing the use of alternative nonanimal test methods by certain Maryland research facilities. The bill defines “alternative nonanimal test method” broadly to include methods such as computational toxicology, bioinformatics, high-throughput screening, in vitro studies, tiered testing, and microphysiological systems, so long as they do not use live vertebrate animals and provide information of equivalent or better scientific quality than traditional animal tests. It also defines “traditional animal test method” as testing using live vertebrate animals to evaluate products such as chemicals, ingredients, drugs, vaccines, or product formulations.
The bill applies only to research facilities in Maryland that are required to file USDA Animal and Plant Health Inspection Service Form 7023. Under the bill, a facility may not use a traditional animal test method if an approved alternative nonanimal method exists or if the relevant federal or state agency has granted or made available a waiver from using animal testing. If a traditional animal test is still allowed, the facility must use the fewest animals possible and minimize pain, suffering, and stress. The bill also excludes certain biomedical research and testing required by federal or state agencies, including situations where an agency expressly concludes animal testing is needed to assess consumer health or safety.
HB1448 requires covered research facilities to file annual reports with the Attorney General beginning in 2027, detailing both traditional animal tests and alternative methods used in the prior year, including the number and species of animals used and any waivers received. The Attorney General must then make those reports publicly available by April 20 each year and is assigned enforcement authority, including the ability to seek injunctive relief in circuit court. The act takes effect January 1, 2026.
The overall sentiment reflected by the bill text is strongly supportive of reducing animal testing where scientifically and regulatorily feasible, while preserving exceptions for federally required testing and biomedical research. Because no committee transcripts or vote records were provided, there is no recorded public debate in the supplied materials, but the structure of the bill suggests an intent to balance animal welfare concerns with regulatory compliance and research needs.
The main points of contention likely center on whether the bill could limit research flexibility, impose reporting burdens, or conflict with federal testing requirements, versus the argument that it promotes humane science and transparency. The bill’s exceptions for agency-required testing and biomedical research appear designed to address those concerns by preventing the prohibition from applying where animal testing is still considered necessary.
The bill would add a new Subtitle 23A to the Health-General Article, creating state-law restrictions on when certain Maryland research facilities may use live vertebrate animal testing. It would require covered facilities to substitute approved nonanimal methods when available, impose animal-minimization standards when animal testing is still permitted, and establish annual reporting and public disclosure requirements enforced by the Attorney General. The bill affects research facilities subject to APHIS Form 7023 reporting and would create new compliance, transparency, and enforcement obligations for those entities.
No committee discussion or vote data were provided, so there is no documented legislative debate in the supplied materials. Based on the bill’s text, the measure appears to be driven by a pro-animal-welfare and pro-alternative-science policy approach, with a clear preference for nonanimal testing methods where feasible. At the same time, the bill includes multiple carveouts for federally or state-required testing and biomedical research, suggesting an effort to avoid overreach and maintain regulatory compatibility.
Likely areas of contention include whether the bill could interfere with product testing, drug development, or compliance with federal agency requirements, and whether the reporting and public disclosure provisions would create administrative burdens for research facilities. Supporters would likely emphasize animal welfare, scientific innovation, and transparency, while opponents or cautious stakeholders may focus on feasibility, cost, and the risk of limiting traditional testing when alternatives are not yet accepted by regulators. The bill’s explicit exceptions for agency-required testing and biomedical research appear aimed at addressing these concerns.